D-4-异丙苯基丙氨酸 | 755724-85-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-4-异丙苯基丙氨酸
• 中文别名: D-4-异丙基苯基丙氨酸；4-异丙基-D-苯丙氨酸
• 英文名称: D-4-Isopropylphenylalanine
• 英文别名: (2R)-2-amino-3-(4-propan-2-ylphenyl)propanoic acid
• CAS: 755724-85-7
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.27
• InChiKey: CYHRSNOITZHLJN-LLVKDONJSA-N

物化性质

• 沸点：
  340.6±30.0 °C(Predicted)
• 密度：
  1.105±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Modulators of ROR-gamma Receptors, Composition and Use Thereof
  申请人：KULING THERAPEUTICS

  公开号：US20170298090A1

  公开（公告）日：2017-10-19

  The present invention provides novel methods to treat disease by modulating retinoid-related orphan receptor gamma (ROR-gamma) in vitro and in vivo with ursolic acid analogs, and compositions thereof. The methods and compounds disclosed herein are useful for inhibiting the differentiation of a population of T cells, or treating a disease related to Th17 cell responses in a subject. Examples of such diseases include, but are not limited to, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis and diabetes.

  本发明提供了一种通过使用熊果酸类似物在体外和体内调节视黄醇相关孤儿受体γ（ROR-gamma）来治疗疾病的新方法，以及相关组合物。本文披露的方法和化合物对于抑制T细胞群体的分化或治疗与Th17细胞反应相关的疾病非常有用。此类疾病的示例包括但不限于自身免疫疾病、多发性硬化症、类风湿性关节炎、牛皮癣和糖尿病。
• STREPTOGRAMINS AND METHOD FOR PREPARING SAME BY MUTASYNTHESIS
  申请人：Aventis Pharma, S.A.

  公开号：US20020142947A1

  公开（公告）日：2002-10-03

  Novel group B streptogramine-like compounds of general formula (I), and a method for preparing streptogramines by muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines, are disclosed. Novel nucleotide sequences involved in the biosynthesis of said precursors, and their uses, are also disclosed.

  本发明公开了通式(I)的新型B组链球菌素类化合物，以及通过使用突变的微生物进行muta合成来影响B组链球菌素的至少一个前体的生物合成的制备方法。还公开了参与所述前体生物合成的新型核苷酸序列及其用途。
• Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
  申请人：Hunter L. William

  公开号：US20080058579A1

  公开（公告）日：2008-03-06

  Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation and a cell-cycle inhibitor
• AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF
  申请人：Silverback Therapeutics, Inc.

  公开号：US20220362396A1

  公开（公告）日：2022-11-17

  Amino-pyrazinecarboxamide compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of cancer and fibrosis and modulating TGFβR2. Additionally, compounds incorporated into a conjugate with an antibody construct are described herein.
• US6352839B1
  申请人：——

  公开号：US6352839B1

  公开（公告）日：2002-03-05